Modified HSV-1 Vector for Suspension Cell Culture Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of herpes simplex virus type 1 (HSV-1) vectors is limited by the requirement for adherent cell lines, which restricts scalability and yield, making it challenging to meet the demands of gene therapy applications.
Innovation Solution
A modified HSV-1 vector with mutations in the US2 and US8 coding sequences, specifically a G276V mutation in US2 and a W116STOP mutation in US8, allowing production in suspension cell lines, and an inactivating deletion of the US8 gene to prevent cell-to-cell spread.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If adherent cell lines are used for HSV-1 vector production, then viral production is achieved, but scalability and manufacturing yield are limited
Solution Approach 1:
The patent applies parameter changes by modifying the viral genome sequence - specifically deleting the US8 gene and mutating the US2 gene - to alter the virus's cellular requirements. This genetic modification enables the virus to be produced in suspension cell lines instead of adherent cell lines, fundamentally changing the cultivation parameter from surface-dependent to suspension-based, thereby resolving the scalability and yield limitations.
2Ease of manufacture
If suspension cell lines are used for HSV-1 vector production, then scalability is improved, but the virus cannot be stably produced without specific modifications
Solution Approach 1:
The patent modifies the viral genome parameters by deleting the US8 gene and mutating the US2 gene (specifically the glycoprotein D gene) to enable stable production in suspension cell lines. These genetic parameter changes are essential for the virus to adapt to and stably replicate in suspension-based cultivation systems, ensuring reliable and scalable production.
3Productivity
If US8 gene is deleted from HSV-1 vector, then cell-to-cell spread is prevented, but production efficiency in suspension cells is enhanced
Solution Approach 1:
The patent applies the extraction principle by completely deleting the US8 gene from the HSV-1 viral genome. This gene deletion removes the functional element responsible for cell-to-cell spread, thereby preventing harmful viral propagation between cells. Simultaneously, this genetic extraction enables the virus to be produced efficiently in suspension cell lines, as the US8 gene is not required for suspension-based viral production.
Solution Approach 2:
The patent changes the genetic parameter of the viral genome by deleting the US8 gene, which fundamentally alters the virus's ability to spread between cells. This parameter change eliminates cell-to-cell spread while enabling efficient production in suspension cell lines, resolving the contradiction between productivity and harmful spread.
Data Source
AI summary
This application describes a modified herpes simplex virus type 1 (HSV-1), capable of being efficiently produced in suspension cell culture, and a method of producing HSV-1 vectors in suspension cell culture.